EGFR and neoplasm: With the exception of a higher tumor burden and a more extensive use of FOLFIRI and cetuximab in the non-maintenance cohort compared to the maintenance cohorts, no significant differences were found regarding the baseline characteristics and prognostic factors, which were fairly balanced among the numerically larger cohorts (i.e., 5FU/LV+anti-EGFR, anti-EGFR, and non-maintenance).